Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes

• Status: Completed
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

evaluate the safety and tolerability of ITCA 650 in subjects with type 2 diabetes mellitus.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Intarcia Therapeutics
• Treatments: Exenatide

Criteria

Inclusion Criteria:

• type 2 diabetes >6 months

• stable diet & exercise, metformin, TZD or met + TZD HbA1c >6.5% <10.0%

Exclusion Criteria:

• prior treatment with exenatide

• history of pancreatitis

• history of medullary thyroid cancer or multiple endocrine neoplasia 2